A triplet regimen is standard therapy for nontransplant patients with multiple myeloma. Patients who cannot tolerate a triplet regimen can be started on a doublet regimen. Currently, the use of quadruplet regimens is reserved for transplant-eligible patients with high-risk double- or triple-hit myeloma. The National Comprehensive Cancer Network (NCCN) guidelines for multiple myeloma list the following combinations as preferred regimens (category 1) for primary induction therapy in patients who are not transplant candidates:
Bortezomib/lenalidomide/dexamethasone
Daratumumab/lenalidomide/dexamethasone
Learn more about the treatment of multiple myeloma.
Editor's Recommendations
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C Besa, Dhaval Shah. Fast Five Quiz: Are You Prepared to Confront Multiple Myeloma? - Medscape - Jan 14, 2022.
Comments